Details of Drug-Drug Interaction
| Drug General Information (ID: DDIUXLBWR5) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Alfuzosin | Drug Info | Verteporfin | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Antihypertensive Agents | Antineoplastics | |||||||
| Structure | |||||||||
| Mechanism of Alfuzosin-Verteporfin Interaction (Severity Level: Moderate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Attenuated pharmacological effects (Unspecific) Click to Show/Hide Mechanism Graph | |||||||||
| Drug Name | Alfuzosin | Verteporfin | |||||||
| Mechanism | Interfere with the therapeutic effect of verteporfin by inhibiting the release of procoagulants or vasoactive factors | Verteporfin | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Pharmacodynamics | ||||||||
| Factor Description | Reduced pharmacological effects leading to insufficient efficacy and/or treatment failure. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | If possible, agents such as anticoagulants, thrombolytics, platelet inhibitors, nonsteroidal anti-inflammatory drugs, ginkgo, dong quai, and vasodilators should be discontinued prior to verteporfin therapy. Otherwise, the potential for diminished efficacy of verteporfin should be considered. | ||||||||
| References | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Product Information. Visudyne (verteporfin) Valeant Pharmaceuticals, Costa Mesa, CA. | ||||||||||||||||||
| 2 | Product Information. Xatral (alfuzosin). Sanofi-Synthelabo Canada Inc, Markham, ON. | ||||||||||||||||||